| |NOVEMBER 202519international standards. Demonstrating its world-class capabilities, the CoE holds ISO 9001, ISO 14001 and ISO 45001 certifications and has been approved by leading regulatory authorities worldwide, including the US FDA, PMDA (Japan), TGA (Australia), NDA (Uganda), HA (Belarus), ANVISA (Brazil), Ministry of Health - Turkey, Drug Controller of India, and EMA (issued by FAMHP-Belgium). To maintain alignment with the latest industry standards and compliance frameworks, the CoE undergoes annual audits by globally recognized bodies such as the US FDA, MHRA, and EU GMP, ensuring that clients remain fully compliant with regulations across their markets."Dedicated to supporting customers with stand-alone analytical requirements, the size and flexibility of our Bengaluru CoE laboratories allow rapid project initiation and concurrent activities. Our proven capacity, experience and expertise in managing extensive stability programs help pharmaceutical companies significantly reduce time-to-market. What truly sets Recipharm's Bengaluru CoE is our deep domain knowledge, global expertise paired with local insight, advanced and customizable technology, and integrated support across product development and manufacturing", adds Dr Ramesh.Recipharm's CoE also leads the way in technological innovation. Guided by QbD (`quality by design') , it leverages high-end automation tools and latest software to ensure scientific precision and systematic product development. The result is output that consistently meetsinternational quality standards, complies with all necessary regulations and exceeds client expectations. With over 500 concurrent stability studies underway, the CoE is managed by a team of highly experienced scientists and equipped state-of-th-art mass spectrophotometers and other advanced instruments, enablingclients to overcome resource constraints, shorten development timelines and optimize costs.The Way ForwardSharing his vision for the future, Dr Ramesh notes, "At Recipharm, we enursue a multidimensional growth strategy that spans across all verticals of the pharmaceutical industry. The recently-inaugurated parenteral and sterility endotoxin laboratories will significantly strengthen our capabilities and expand our capacity in parenteral product development. Looking ahead, we will continue to align our growth and expansion initiatives with evolving customer needs and dynamic market demand". POQUICK FACTS· Year of Inception: 1995· Office Locations: Headquartered in Stockholm (Swe-den), with 17 manufacturing and R&D facilities across US, Europe, Israel and India (CoE in Bengaluru)· Key Services: Pharma analytical testing, product development, manufacturing, technology transfer, regulatory compliance and many more.
< Page 9 | Page 11 >